© PR Newswire
28.04.2025
ATNM
LISTED
XASE
Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annua
News Preview
Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML modelsActimab-A is the only CD33 targeted radiotherapy with Actinium-225 isotope payload in development for AML and other myeloid malignanciesActim...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.04.2025
RXRX
LISTED
NASDAQ
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
News Preview
Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.04.2025
GMAB
LISTED
CPH
Transactions in Connection with Share Buy-back Program
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
28.04.2025
NSIS B
LISTED
CPH
Transactions under Novonesis’ share buyback program
News Preview
Please read the announcement in PDF...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
26.04.2025
SKYE
LISTED
NASDAQ
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on April 23, 2025, the Board of Directors granted a non-qualified stock option award to purchase 19,000 shares of its commo...
Themefolio
Profiler
Peergroup
© BusinessWire
25.04.2025
ZLAB
LISTED
NASDAQ
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, next-generation, investigational oncology therapies that it has global rights to, ZL-6201, a novel leucine-rich repeat-containing protein 15 (LRRC15) antibody-drug conjugate (ADC) targeting multiple solid tumors, and ZL-1222, a...
Themefolio
Profiler
Peergroup
© ActuNews
25.04.2025
OXUR
LISTED
EURONEXT
Oxurion announces that the transaction of July 2024 is stopped and confirms continuation of discussions regarding the acquisition project announced in March 2025
News Preview
LEUVEN, BELGIUM – April 25, 2025 - 6:30 pm, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces today that negotiations initiated in July 2024 concerning the acquisition of a majority stake in a French CRO specialized in stem cells have been stopped by mutual agreement. Despite initial mutual i...
Themefolio
Profiler
Peergroup
© ActuNews
25.04.2025
OXUR
LISTED
EURONEXT
Oxurion annonce l'arrêt de la transaction de juillet 2024 et confirme la poursuite des discussions sur le projet d'acquisition annoncé en mars 2025
News Preview
Louvain, BELGIQUE – 25 avril 2025 – 18h30, Oxurion NV (Euronext Bruxelles : OXUR), entreprise biopharmaceutique basée à Louvain, annonce aujourd'hui que les négociations initiées en juillet 2024, concernant l'acquisition d'une participation majoritaire dans une CRO française spéciali...
Themefolio
Profiler
Peergroup
© ActuNews
25.04.2025
OXUR
LISTED
EURONEXT
Oxurion kondigt stopzetting aan van de transactie van juli 2024 en bevestigt de voortzetting van de gesprekken over het overnameproject aangekondigd in maart 2025
News Preview
LEUVEN, BELGIË – 25 april 2025 - 18:30 uur, Oxurion NV (Euronext Brussels: OXUR), een biofarmaceutisch bedrijf met hoofdzetel in Leuven, kondigt vandaag aan dat de onderhandelingen die in juli 2024 werden opgestart over de verwerving van een meerderheidsbelang in een Franse CRO gespecialiseerd in stamcellen, in onderling overleg zijn sto...
Themefolio
Profiler
Peergroup
© PR Newswire
25.04.2025
CAMX
LISTED
STO
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU
News Preview
LUND, Sweden, April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for market authorization of Oczyesa®, octreotide subcutaneous depot (CAM2029), for the maintenance treatment in adult patients with acrome...
Themefolio
Profiler
Peergroup
© PR Newswire
25.04.2025
CAMX
LISTED
STO
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU
News Preview
LUND, Sweden, April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for market authorization of Oczyesa®, octreotide subcutaneous depot (CAM2029), for the maintenance treatment in adult patients with acrome...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.04.2025
AUTL
LISTED
NASDAQ
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
News Preview
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
25.04.2025
TEM
LISTED
NASDAQ
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including one oral presentation, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, on April 25 - 30 in Chicago. Tempus resear...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.04.2025
ORNBV
LISTED
HEL
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS25 April 2025 at 17.20 EEST ...
Themefolio
Profiler
Peergroup
© PR Newswire
25.04.2025
RAY B
LISTED
STO
Invitation to presentation of RaySearch's interim report for the first quarter of 2025
News Preview
STOCKHOLM, April 25, 2025 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the first quarter of 2025, on May 9, 2025, at 10.00 am CEST. The report will be published on May 9, 2025, at 07.45 am and will be available together with presentation slides on raysearchlabs.com. Johan Löf,...
Themefolio
Profiler
Peergroup
© PR Newswire
25.04.2025
RAY B
LISTED
STO
Odense University Hospital selects RayStation
News Preview
STOCKHOLM, April 25, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that Odense University Hospital (OUH), which is part of the South Denmark Region, has placed an order for RayStation®*.
The radiotherapy center at OUH is known for being at the forefront of automated solutions to provide high-quality care in an efficient way, in...
Themefolio
Profiler
Peergroup
© PR Newswire
25.04.2025
SOBI
LISTED
STO
Sobi and Sanofi's Foundation S extend partnership with the World Federation of Hemophilia Humanitarian Aid Program
News Preview
Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial assistanceSTOCKHOLM, April 25, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) together with the World Federation of Hemophilia (WFH) and Sanofi, through its philanthropic organisation Foundation S, announced the signing of a contract provi...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.04.2025
ORNBV
LISTED
HEL
Orion and Criceto Announce a License Agreement for APORON®, an Innovative Apomorphine Spray to Treat OFF Episodes in Parkinson’s Disease
News Preview
ORION CORPORATION PRESS RELEASE 25 APRIL 2025 at 9.00 EEST ...
Themefolio
Profiler
Peergroup
© EQS Newswire
24.04.2025
MRK
LISTED
XETR
Merck bestätigt weit fortgeschrittene Gespräche mit SpringWorks Therapeutics, Inc. zu möglicher Übernahme
News Preview
Darmstadt, 24. April 2025 – Merck KGaA (“Merck”) reagiert auf Medienberichte und bestätigt, dass sich Merck in weit fortgeschrittenen Gesprächen mit SpringWorks Therapeutics, Inc. zu einer möglichen Übernahme befindet. Die Parteien befinden sich in Gesprächen auf der Basis eines Preises von rund USD 47 pro Aktie.
Merck bestätigt, dass keine abschl......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.04.2025
MRK
LISTED
XETR
Merck confirms late-stage discussions with SpringWorks Therapeutics, Inc. on potential acquisition
News Preview
Darmstadt, April 24, 2025 – Merck KGaA (“Merck”) reacts to press reports and confirms late-stage discussions with SpringWorks Therapeutics, Inc. on a potential acquisition. The parties are in discussion on the basis of a price of around USD 47 per share. Merck notes that no final decision has been taken and no legally binding agreement has been ent......
Themefolio
Profiler
Peergroup
© Globe Newswire
24.04.2025
GNFT
LISTED
EURONEXT
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
News Preview
Lille, France; Cambridge, MA; Zurich, Switzerland; April 24, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced annual financial results for the year ended December 31, 2024. A summary of the consolidated financ...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.04.2025
CLARI
LISTED
EURONEXT
Clariane I 2025 first-quarter revenue
News Preview
...
Themefolio
Profiler
Peergroup
© PR Newswire
24.04.2025
CYRX
LISTED
NASDAQ
Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025
News Preview
NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 7, 2025 after U.S. markets close....
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
TEM
LISTED
NASDAQ
Tempus to Report First Quarter 2025 Financial Results on May 6
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day.
The call will featu...
Themefolio
Profiler
Peergroup
© EQS Newswire
24.04.2025
EUZ
LISTED
XETR
Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm
News Preview
Berlin, 24 April 2025. Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE, today announced the signing of a manufacturing agreement with Pentixapharm, a clinical-stage biopharmaceutical company. Under the terms of the agreement, EZR will produce and distribute patient-specific doses of Y90-PentixaTher, Pentixa......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.04.2025
EUZ
LISTED
XETR
Eckert & Ziegler unterzeichnet Herstellungsvereinbarung mit Pentixapharm für Yttrium-90-basiertes PentixaTher
News Preview
Berlin, 24. April 2025. Die Eckert & Ziegler Radiopharma GmbH (EZR), eine 100%ige Tochtergesellschaft der Eckert & Ziegler SE, hat heute eine Vereinbarung zur Auftragsherstellung mit Pentixapharm, einem biopharmazeutischen Unternehmen in klinischer Entwicklung bekanntgegeben. Im Rahmen der Zusammenarbeit wird EZR patientenindividuelle Dosen......
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
DFTX
LISTED
NASDAQ
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025
News Preview
Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, May 8, 2025 to report financial results for the first quarter ended March 31, 2...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
OGI
LISTED
NASDAQ
Organigram Global’s Products Recognized at the CNB Awards
News Preview
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada’s #1 cannabis company by market share, is pleased to announce that three of its consumer brands — SHRED, Edison, and Trailblazer — earned honours at the recent CNB Leadership Conference and the Cannabis NB Cup.
This press release features multimedia. View the...
Themefolio
Profiler
Peergroup
© PR Newswire
24.04.2025
HNSA
LISTED
STO
Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results
News Preview
Strong product sales and key progress in pipeline catalysts
LUND, Sweden, April 24, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced its interim report for January-March 2025.
Peter Nicklin, Chairman of the Board, Hansa Biopharma said, "In Q1, the Company delivered strong growth with tot...
Themefolio
Profiler
Peergroup
© PR Newswire
24.04.2025
HNSA
LISTED
STO
Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results
News Preview
Strong product sales and key progress in pipeline catalysts
LUND, Sweden, April 24, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced its interim report for January-March 2025.
Peter Nicklin, Chairman of the Board, Hansa Biopharma said, "In Q1, the Company delivered strong growth with tot...
Themefolio
Profiler
Peergroup
© PR Newswire
24.04.2025
VITR
LISTED
STO
Vitrolife AB (publ) Interim report Q1, 2025: Strong performance in EMEA
News Preview
GOTHENBURG, Sweden, April 24, 2025 /PRNewswire/ --
First quarter
Sales of SEK 842 (841) million, an increase of 1% in local currencies and 0% in SEK. The growth in local currencies excluding discontinued business was 3%. Sales per region, in local currencies was +8% in EMEA, +14% excluding discontinued business, +9% in Americas and -15% in APAC...
Themefolio
Profiler
Peergroup
© PR Newswire
24.04.2025
INDV
LISTED
NASDAQ
Indivior Announces Q1 2025 Financial Results
News Preview
SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at www.indivior.com....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.04.2025
ORNBV
LISTED
HEL
Composition of the Nomination Committee of Orion Corporation
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE24 APRIL 2025 at 11.00 EEST ...
Themefolio
Profiler
Peergroup
© EQS Newswire
24.04.2025
EVT
LISTED
XETR
Evotec verkündet starke Fortschritte in strategischer Kollaboration mit Bristol Myers Squibb im Bereich Protein Degradation
News Preview
Wichtige wissenschaftliche Erfolge treiben die Erweiterung der Pipeline von Molecular Glue Degraders für ungedeckte medizinische Bedürfnisse voran
Leistungs- und programmabhängige Zahlungen an Evotec in Höhe von insgesamt 75 Mio. US$
Hamburg, 24. April 2025:
Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE000......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.04.2025
EVT
LISTED
XETR
Evotec announces significant progress in strategic protein degradation collaboration with Bristol Myers Squibb
News Preview
Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs
Performance-based and program-based payments of in total US$ 75 m to Evotec
Hamburg, Germany, 24 April 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced furt......
Themefolio
Profiler
Peergroup
© Globe Newswire
24.04.2025
ZEAL
LISTED
CPH
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes
News Preview
Press release – No. 6 / 2025...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
24.04.2025
EVT
LISTED
XETR
Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb
News Preview
Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needsPerformance-based and program-based payments of in total US$ 75 m to Evotec HAMBURG, DE / ACCESS Newswire / April 24, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced further signi...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
ZLAB
LISTED
NASDAQ
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating ZL-1310, the Company’s potential first-in-class and best-in-class, Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for the treatment of extensive-stage small cell lung cancer (ES-SCLC), wil...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
TEM
LISTED
NASDAQ
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collaborations with AstraZeneca (LSE/STO/Nasdaq: AZN) and Pathos AI, Inc., in which the companies will work together to build a multimodal foundation model in oncology which can be use...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
HELP
LISTED
NASDAQ
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced additional strategic partnership agreements (“SPAs”), bringing the total to 18 c...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.04.2025
ZEAL
LISTED
CPH
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery
News Preview
Press release – No. 5 / 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.04.2025
ORNBV
LISTED
HEL
Orion Group Interim Report January–March 2025
News Preview
ORION CORPORATION INTERIM REPORT 1–3/2025 23 APRIL 2025 at 12:00 EEST...
Themefolio
Profiler
Peergroup
© PR Newswire
23.04.2025
SOBI
LISTED
STO
Sobi presents clinical data at WFH 2025 Comprehensive Care Summit
News Preview
STOCKHOLM, April 23, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) presents clinical data aimed at updating the global haemophilia community attending this year's WFH 2025 Comprehensive Care Summit in Dubai from the 23 – 25 April. New and updated outcomes and analyses will be presented from the XTEND phase 3clinical program testing the effectiveness of...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.04.2025
RXRX
LISTED
NASDAQ
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
News Preview
Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data during the 2025 Digestive Disease Week (DDW) meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.04.2025
NSIS B
LISTED
CPH
Andrew Taylor joins Novonesis’ Executive Leadership Team
News Preview
Andrew Taylor will assume the role as EVP of Food & Beverage Biosolutions at Novonesis....
Themefolio
Profiler
Peergroup
© PR Newswire
22.04.2025
GETI B
LISTED
STO
Getinge Interim Report January-March 2025: Strong sales and improved earnings - continued focus on customer value and profitability going forward
News Preview
GOTHENBURG, Sweden, April 22, 2025 /PRNewswire/ -- "We are entering 2025 with healthy organic sales growth and improved adjusted operating profit despite headwinds from currency effects," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales increased organically by 6.2% while the order intake rose by 2.9% organical...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.04.2025
NSIS B
LISTED
CPH
Transactions under Novonesis’ share buyback program
News Preview
Please read the announcement in PDF...
Themefolio
Profiler
Peergroup
© PR Newswire
22.04.2025
GETI B
LISTED
STO
Getinge Interim Report January-March 2025: Strong sales and improved earnings - continued focus on customer value and profitability going forward
News Preview
GOTHENBURG, Sweden, April 22, 2025 /PRNewswire/ -- "We are entering 2025 with healthy organic sales growth and improved adjusted operating profit despite headwinds from currency effects," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales increased organically by 6.2% while the order intake rose by 2.9% organical...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
OGI
LISTED
NASDAQ
Organigram Global Shares Recording of its OG Investor Session
News Preview
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram Global”), Canada’s #1 cannabis company by market share, is pleased to share the full recording of its recently held OG Investor Session, now available online for shareholders, analysts, and industry stakeholders.
This press release features multimedia. View the full rel...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.04.2025
GMAB
LISTED
CPH
Transactions in Connection with Share Buy-back Program
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.04.2025
AUTL
LISTED
NASDAQ
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
News Preview
Autolus will report Q1 2025 financial results on May 8, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.04.2025
ORNBV
LISTED
HEL
Invitation to Orion’s Capital Markets Day on 22 May 2025
News Preview
ORION CORPORATION INVESTOR NEWS 22 APRIL 2025 at 9.00 EEST...
Themefolio
Profiler
Peergroup
© BusinessWire
21.04.2025
DFTX
LISTED
NASDAQ
MindMed Announces New Employee Inducement Grants
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 121,500 commo...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.04.2025
GLPG
LISTED
EURONEXT
Galapagos Announces Executive Leadership Updates
News Preview
Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo ...
Themefolio
Profiler
Peergroup
© BusinessWire
21.04.2025
HELP
LISTED
NASDAQ
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced a strategic partnership with Osmind, a leading service provider advancing psychiatry thro...
Themefolio
Profiler
Peergroup
© BusinessWire
21.04.2025
SLP
LISTED
NASDAQ
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced its support of the U.S. Food and Drug Administration’s (FDA) recently announced roadmap for reducing animal...
Themefolio
Profiler
Peergroup
© BusinessWire
21.04.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The application is intended...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.04.2025
INSP
LISTED
NYSE
Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors
News Preview
MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.04.2025
ORY
LISTED
BME
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
News Preview
New “Decision to grant” communications in Europe and Japan New “Decision to grant” communications in Europe and Japan...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.04.2025
ZEAL
LISTED
CPH
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
News Preview
Company announcement – No. 10 / 2025...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
